La vendita allo scoperto per Genmab dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Genmab. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Genmab (NASDAQ:GMAB) Azioni, Report sulle vendite allo scoperto

GENMAB A/S -SP ADR

Genmab

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS

Seaport Global analyst Jeff Cantwell upgrades Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) from Neutral to Buy and maintains the price target from $616 to $616.

News

Upgrades

Price Target

Analyst Ratings

Seaport Global Upgrades Mastercard to Buy, Maintains Price Target to $616

Baird analyst Jeff Johnson downgrades Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) from Outperform to Neutral and lowers the price target from $82 to $72.

Downgrades

HSIC

Baird Downgrades Henry Schein to Neutral, Lowers Price Target to $72

Airline begins adding new destinations to its network for the first time since 2021
DALLAS, July 14, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4467241-1&amp;h=4199715501&amp;u=http%3A%2F%2Fwww.southwest.com%2F%3Fsrc%3DPRPRPRNSTTUSV250714&amp;a=Southwest+Airlines+Co.%C2%A0">Southwest Airlines Co.&nbsp;</a>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) intends to grow its network in 2026 initially with new service at Cyril E. King International Airport (STT) on St. Thomas, adding the U.S. Virgin Islands to the carrier's tropical destinations in the Caribbean. Service is expected to begin in early 2026&#x2A; and will be available for purchase soon.

Southwest Airlines Intends To Grow Network In 2026 Initially With New Caribbean Service To U.S. Virgin Islands

Baird analyst Joe Vruwink upgrades Ncino (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) from Neutral to Outperform and raises the price target from $30 to $38.

NCNO

Baird Upgrades Ncino to Outperform, Raises Price Target to $38

On July 14, 2025, NextCure, Inc., a Delaware corporation (the "Company"), effected a one-for-twelve (1:12) reverse stock split ("Reverse Stock Split") of the Company's common stock, par value $0.001 (the "Common Stock"). As previously disclosed, at the annual meeting of stockholders of the Company held on June 20, the stockholders of the Company approved an amendment to the Company's Third Amended and Restated Certificate of Incorporation (the "Amendment") to effect a&nbsp;reverse stock split&nbsp;at a ratio in the range of one-to-five (1:5) to one-to-fifteen (1:15), with such ratio to be subsequently determined in the discretion of the Company's board of directors (the "Board").
&nbsp;
Pursuant to such authority granted by the Company's stockholders, the Board approved the&nbsp;Reverse Stock Split&nbsp;of the Common Stock, and the filing of the Amendment to effectuate the&nbsp;Reverse Stock Split. The Amendment became effective at&nbsp;12:01 a.m. Eastern Time on July 14, 2025.
&nbsp;
The Reverse Stock Split will affect all shares of Common Stock outstanding immediately prior to the effective time of the Reverse Stock Split. In addition, the Reverse Stock Split will effect a reduction in the number of shares of Common Stock (i) available for issuance under the Company's 2019 Omnibus Plan and 2019 Employee Stock Purchase Plan, (ii) to be automatically added to the number of shares available for issuance under the 2019 Employee Stock Purchase Plan pursuant to the annual "evergreen" provision of such plan, and (iii) issuable upon the exercise of stock options outstanding immediately prior to the effectiveness of the Reverse Stock Split. To reflect the Reverse Stock Split, there will also be a corresponding increase in the exercise price per share applicable to outstanding stock options. The number of authorized shares of Common Stock will remain at 100 million shares.
&nbsp;
No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to a fractional share of Common Stock are instead entitled to a check representing the cash value equal to the fraction to which the stockholder would otherwise be entitled, multiplied by the closing price of the Common Stock, as reported by Nasdaq, on the last trading day prior to the effective date of the Reverse Stock Split.
The Common Stock is scheduled to begin trading on the Nasdaq Global Select Market on a split-adjusted basis when the market opens on July 14, 2025 under the existing ticker symbol "NXTC".

Stock Split

NXTC

NextCure Enacts 1-for-12 Reverse Stock Split, Shares Begin Trading Today on Adjusted Basis

CICC analyst Shiwen Li initiates coverage on Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) with a Outperform rating and announces Price Target of $78.

Initiation

CSCO

CICC Initiates Coverage On Cisco Systems with Outperform Rating, Announces Price Target of $78

SONN: 300% &#x7C; <a href="https://www.benzinga.com/node/46387440">Sonnet Biotherapeutics Announces A Business Combination With Rorschach, A Newly-formed Entity Formed By Atlas Merchant Capital, An Affiliate Of Paradigm Operations, And Additional Sponsors, To Build A Reserve Of HYPE, The Token Of The Hyperliquid Layer-1 Blockchain</a>
&nbsp;
LION: 27% &#x7C; L<a href="https://www.benzinga.com/node/46377466">ionsgate shares are trading higher after Bloomberg reported that Legendary is weighing a buyout.</a>
&nbsp;
YHC: 100% &#x7C; <a href="https://www.benzinga.com/node/46387951">Robert Leshner Reported A 56.9% Stake In LQR House In 13D Filing</a>

Movers

Trading Ideas

LION

SONN

Market-Moving News for July 14th

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk&#8216;s push for a 25% voting power in the electric vehicle maker is pivotal for the company&#8217;s <a href="https://www.benzinga.com/markets/tech/25/07/46386582/elon-musk-wants-tesla-to-invest-in-xai-but-its-up-to-shareholders-this-analyst-says-grok-is-worth-the-bet">potential investment in xA</a>I, according to Wedbush Securities analyst Daniel Ives.
What Happened: In a recent X post, Ives emphasized that this &#8220;level is the key&#8221; for Tesla&#8217;s strategic move into artificial intelligence, aligning with Musk&#8217;s vision to integrate xAI&#8217;s capabilities, such as the Grok chatbot, into Tesla&#8217;s ecosystem.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We believe Tesla making a big investment in xAI is a key step forward and something <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@elonmusk</a> supports. We believe getting Musk to 25% voting level is key for AI …all of this will be the focus of Board among other things as we discussed. &#x1f525;&#x1f3af;&#x1f447; <a href="https://t.co/okdGWtvjSu">https://t.co/okdGWtvjSu</a>
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1944681594234765662?ref_src=twsrc%5Etfw">July 14, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
This comes as Musk, currently holding a 22% equity stake in Tesla, seeks to bolster his control amid discussions of a shareholder vote on investing in xAI, reported <a href="https://www.bloomberg.com/news/articles/2025-07-14/musk-suggests-tesla-shareholders-will-vote-on-xai-investment">by</a> Bloomberg on July 14.
Musk&#8217;s current voting power, enhanced by Tesla&#8217;s supermajority voting rules requiring two-thirds approval for major changes, already grants him significant influence.
However, Ives argues that 25% is critical for navigating the complexities of AI development and potential mergers, especially after xAI&#8217;s $33 billion acquisition of X and a reported $198.3 million spend on Tesla services, including Megapacks, as per a 2025 Bloomberg analysis.
Despite Musk&#8217;s readiness for a shareholder vote, as he stated on X, &#8220;It's not up to me. If it was up to me, Tesla would have invested in xAI long ago,&#8221; challenges persist.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">It's not up to me. If it was up to me, Tesla would have invested in xAI long ago. We will have a shareholder vote on the matter.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1944534221672104233?ref_src=twsrc%5Etfw">July 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/politics/25/07/46386524/trump-wants-blanket-tariffs-of-up-to-20-after-surprise-treasury-surplus-in-june-ed-yardeni-says-don">Trump Wants Blanket Tariffs Of Up To 20% After Surprise Treasury Surplus In June: Ed Yardeni Says &#8216;Don&#8217;t Push Your Luck&#8217;</a>
Why It Matters: The Tesla boss had asked X users last year if Tesla should invest $5 billion in xAI. However, he had acknowledged that the robotaxi maker&#8217;s board and backers would need to green-light such a decision.
As Tesla shareholders prepare for this decision, the 25% threshold emerges as a battleground for control and innovation in Musk&#8217;s corporate empire.
Gene Munster, managing partner at&nbsp;Deepwater Asset Management, <a href="https://www.benzinga.com/markets/tech/25/07/46386582/elon-musk-wants-tesla-to-invest-in-xai-but-its-up-to-shareholders-this-analyst-says-grok-is-worth-the-bet">quickly weighed in</a>, saying, &#8220;If Tesla&#8217;s future is autonomy, then Tesla investors and the board should support the investment.&#8221;
&#8220;xAI can help power that future either as a partner or part of Tesla. The faster they can get cash, the higher the odds of success for both companies.&#8221;
Shares of Tesla have fallen by 17.34% on a year-to-date basis, but they were higher by 24.09% over the past year. It was up 0.95% in premarket on Monday.
Benzinga Edge Stock Rankings shows that TSLA had a stronger price trend over the medium and long term but a weaker trend over the short term. Its momentum ranking was moderate, whereas its value ranking was poor; the details of all the metrics are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="161" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14062944/Edge-Tesla-new-latest-1024x161.png" alt="" class="wp-image-983695" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14062944/Edge-Tesla-new-latest-1024x161.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14062944/Edge-Tesla-new-latest-300x47.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14062944/Edge-Tesla-new-latest-768x121.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14062944/Edge-Tesla-new-latest.png 1048w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Monday. The SPY was down 0.29% at $621.80, while the QQQ declined 0.29% to $552.58, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/hedge-funds/25/07/46386374/stanley-druckenmillers-duquesne-dumps-palantir-bets-big-on-this-dividend-play-which-has-surged-nearly-50-in-2025">Stanley Druckenmiller&#8217;s Duquesne Dumps Palantir, Bets Big On This Dividend Play Which Has Surged Nearly 50% In 2025</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. 
Image Credit: Mike Tripp/The News Leader Via Imagn

TSLA

Tesla Investment In xAI Hinges On Elon Musk Having 25% Voting Power: 'Level Is Key,' Says Dan Ives

Seaport Global analyst Scott Graham initiates coverage on Ralliant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAL#NYSE">RAL</a>) with a Neutral rating.

Seaport Global Initiates Coverage On Ralliant with Neutral Rating

CELC

Celcuity Expects To Announce Topline Data For PIK3CA Wild-Type Cohort Of VIKTORIA-1 Clinical Trial In Q3 2025; Expects To Report Topline Data For PIK3CA Mutant Cohort In Q4 2025

Celcuity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the issuance of U.S. Patent No. 12,350,276 covering the clinical dosing regimen for its lead drug candidate, gedatolisib, in ER+/HER2- breast cancer patients. The patent extends Celcuity's patent exclusivity in the U.S. into 2042.
Celcuity expects to announce topline data for the PIK3CA wild-type cohort of the VIKTORIA-1 clinical trial in the third quarter of 2025 and to report topline data for the PIK3CA mutant cohort in the fourth quarter of 2025.

Celcuity Announces Issuance Of U.S. Patent Covering Clinical Dosing Regimen For Gedatolisib In ER+/HER2- Breast Cancer Patients, Extending Celcuity's Patent Exclusivity In U.S. Into 2042

DCOM

Dime Adds Fifth Vertical With Lender Finance, Deepening Focus On Private Equity And Private Credit Clients

Celcuity Granted New U.S. Patent For Gedatolisib Dosing Regimen, Extending Patent Exclusivity Through 2042

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OSTX#AMEX">OSTX</a>) with a Buy and maintains $20 price target.

OSTX

D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target

I-Mab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in the BTIG Virtual Biotechnology Conference, being held on July 29-30, 2025.
Conference details are as follows:
BTIG Virtual Biotechnology Conference Format: Fireside Chat and one-on-one meetings Date: Tuesday, July 29, 2025 Time: 10:00 AM ET Webcast Link: Available on the News &amp; Events page of the I-Mab website
The webcast of the event will be accessible from News &amp; Events page of the&nbsp;I-Mab&nbsp;website for 90 days.

IMAB

I-Mab to Join Virtual Biotech Event, Talks Cancer Treatment Progress With Investors

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Rxsight Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>)</h3>
<ul class="wp-block-list">
<li>On July 8, RxSight cut its 2025 revenue guidance from $160 million–$175 million to $120 million–$130 million. &#8220;Guided by insights from our second quarter underperformance and building on our long-term vision, we are evolving our commercial approach to re-direct more of our focus toward supporting customer success within new and existing practices,&#8221; said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight. The company's stock fell around 39% over the past five days and has a 52-week low of $6.32.</li>
<li>RSI Value: 20.9</li>
<li>RXST Price Action: Shares of Rxsight fell 5.4% to close at $8.00 on Friday.</li>
<li>Edge Stock Ratings: 1.77 Momentum score with Value at 73.93. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/rxst"><img loading="lazy" decoding="async" width="416" height="183" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070107/image-149.png" alt="" class="wp-image-983751" style="width:284px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070107/image-149.png 416w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070107/image-149-300x132.png 300w" sizes="(max-width: 416px) 100vw, 416px" /></a></figure>
<h3 class="wp-block-heading">Sarepta Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On June 25, HC Wainwright &amp; Co. downgraded the stock from Neutral to Sell and cut its price target on the stock from $40 to $10. The company's stock fell around 13% over the past month and <a href="https://www.benzinga.com/quote/SRPT">has a 52-week low</a> of $16.88.</li>
<li>RSI Value: 27</li>
<li>SRPT Price Action: Shares of Sarepta Therapeutics fell 4.7% to close at $18.17 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0714">SRPT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0714"><img loading="lazy" decoding="async" width="935" height="861" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070217/image-150.png" alt="" class="wp-image-983752" style="width:627px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070217/image-150.png 935w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070217/image-150-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070217/image-150-768x707.png 768w" sizes="(max-width: 935px) 100vw, 935px" /></a></figure>
<h3 class="wp-block-heading">TransMedics Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>)</h3>
<ul class="wp-block-list">
<li>On May 8, TransMedics Group reported better-than-expected first-quarter financial results and raised its FY25 sales guidance above estimates. &#8220;Overall, we are very pleased with our first quarter performance, which we believe underscores the unique attributes of our business and the ability to deliver strong top and bottom-line financial results,&#8221; said Waleed Hassanein, MD, President and Chief Executive Officer. The company's stock fell around 21% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/TMDX">low of $55.00</a>.</li>
<li>RSI Value: 27.1</li>
<li>TMDX Ltd Price Action: Shares of TransMedics fell 9.9% to close at $112.46 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0714">TMDX shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0714"><img loading="lazy" decoding="async" width="888" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070534/image-151.png" alt="" class="wp-image-983758" style="width:667px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070534/image-151.png 888w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070534/image-151-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/14070534/image-151-768x720.png 768w" sizes="(max-width: 888px) 100vw, 888px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46364472/top-3-real-estate-stocks-that-may-fall-off-a-cliff-this-month">Top 3 Real Estate Stocks That May Fall Off A Cliff This Month</a></li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

RXST

SRPT

TMDX

Top 3 Health Care Stocks That Could Blast Off In July

First Community Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCCO#NASDAQ">FCCO</a>) ("First Community" or "FCCO"), the holding company of First Community Bank, and Signature Bank of Georgia (OTCPK: SGBG) ("Signature" or "SGBG") jointly announced today the signing of a definitive merger agreement, under which First Community has agreed to acquire Signature in an all-stock transaction with a total current value of approximately $41.6 million, based on First Community's closing price of $24.84 per share as of July 11, 2025. The transaction value at the time of the merger may change due to changes in the price of First Community stock.
On a pro forma combined basis, the combined company is expected to have approximately $2.3 billion in total assets, $2.0 billion in total deposits, and $1.5 billion in total loans at closing. The transaction will create a 23-office banking company with locations spanning the Midlands,&nbsp;Aiken, Upstate, and Piedmont Regions of South Carolina, the Augusta, Georgia area, and now the Atlanta-Sandy Springs-Roswell, Georgia MSA. The merger agreement has been unanimously approved by the Board of Directors of each company. Closing of the transaction, which is expected to occur early in the first quarter of 2026, is subject to customary conditions, including regulatory approval and approval by the shareholders of Signature and First Community.&nbsp;
Per the merger agreement, Signature shareholders will have the right to receive 0.6410 shares of First Community common stock for each share of Signature common stock. The merger is expected to enhance First Community's tangible common equity to tangible assets (TCE/TA) ratio by approximately 35&nbsp;basis points, resulting in a pro forma ratio of 7.45%. It is projected to be accretive to First Community's earnings per share by approximately 4.4% in 2026, the first year of combined operations. The transaction structure anticipates tangible book value dilution of approximately 2.6%, with an earnback period of 2.2 years. The internal rate of return on the deal is estimated at approximately 27.6%, reflecting the strong financial and strategic merits of the transaction.

FCCO

SGBG

First Community Agrees To Acquire Signature In All-Stock Transaction With Total Current Value Of ~$41.6M

Gastrointestinal biomarker tests enhance patient diagnosis of&nbsp;IBD and pancreatic insufficiency on leading clinical chemistry platforms

QDEL

QuidelOrtho And BÜHLMANN Expand Access To Fecal Biomarker Testing With Integration Of Turbo Assays On VITROS Platforms

Hedge Funds

General

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

ASL Strategic Value Fund Urdes Avadeln Shareholders To Vote Against All Director Nominees, Calls For Independent Oversight Of Annual Meeting Vote

Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients with uncontrolled or treatment resistant hypertension received baxdrostat or placebo on top of standard of care. Baxdrostat was generally well tolerated with a favorable safety profile.
There are 1.3 billion people worldwide living with hypertension.1 When uncontrolled, hypertension can lead to a higher risk of heart attack, stroke, heart failure and kidney disease.2,3 In the US, approximately 50% of hypertensive patients who are on multiple treatments do not have their blood pressure under control.4 Growing evidence points to aldosterone dysregulation as one of the key biological drivers of hypertension.5,6
Dr. Bryan Williams, Chair of Medicine at University College London, primary investigator, said: "Many people continue to struggle with high blood pressure that is hard to control, even when taking multiple medications. The highly promising BaxHTN Phase III results show that once-daily baxdrostat on top of standard of care can meaningfully lower systolic blood pressure and offer a potential new treatment approach for controlling hypertension, the leading risk factor for cardiovascular disease."
Sharon Barr, Executive Vice President, BioPharmaceuticals R&amp;D, said: "We are very excited with the BaxHTN Phase III results, which show statistically significant and clinically meaningful reductions in systolic blood pressure. These findings provide compelling evidence of baxdrostat's potential to address a critical unmet need by targeting aldosterone dysregulation, bringing a novel mechanism to a field that has seen little innovation in over two decades."
BaxHTN is a Phase III, multicenter, randomized, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of baxdrostat in patients with uncontrolled hypertension being treated with two different antihypertensive medications and patients with resistant hypertension being treated with three or more different antihypertensive medications, one of which is a diuretic.7
The data will be shared with regulatory authorities around the world and presented in a late‑breaking Hot Line session at the European Society of Cardiology (ESC) Congress in August 2025.
Baxdrostat is a potential first-in-class, highly selective aldosterone synthase inhibitor (ASI) that targets the hormone driving elevated blood pressure and increased cardiovascular and renal risk. It is currently being investigated in clinical trials as a monotherapy for hypertension8,9 and primary aldosteronism,10 and in combination with dapagliflozin for chronic kidney disease and the prevention of heart failure in high-risk hypertensive patients.11-13

AstraZeneca's New Drug Baxdrostat Significantly Lowers Blood Pressure in Late-Stage Trial

Press Releases

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Comments

Genmab

Vendite allo scoperto

Genmab (NASDAQ:GMAB) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO